Novartis to Buy Breast-Cancer Drug From Synnovation for Up to $3 Billion

3 weeks ago 17

SNV4818 is being evaluated successful an aboriginal and mid-stage survey for bosom crab and different precocious coagulated tumors, Novartis said.